The World Health Organization has ‘pre-qualified’ Coartem® Baby, the first-ever malaria treatment for young infants of 4.5 kilograms or less. The combination treatment, now being rolled out in Ghana, aims to fill a longstanding gap in treatments available for children under the age of 5, who constitute three quarters of the estimated 610,000 malaria deaths […] Continue reading ->
GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an  advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts […] Continue reading ->
The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates.  A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading ->
The first pregnant woman infected with malaria has been recruited into a Phase 3 trial in Mali that is evaluating the efficacy and safety of antimalarial drugs during the first trimester of pregnancy. Pregnant women are more susceptible to malaria as they have reduced immunity, and malaria poses serious risks to both mothers and babies. […] Continue reading ->
A new declaration by health ministers from African countries that have the highest malaria burden has reaffirmed the “unwavering commitment to the accelerated reduction of malaria mortality”. The declaration, issued Wednesday by ministers convening in Yaoundé, Cameroon at an African-wide WHO conference on malaria, aims to revitalise the campaign to drive deaths from malaria further […] Continue reading ->
A standardized set of more than 80 compounds with known or predicted activity against SARS-CoV-2, the virus that causes COVID-19, has been compiled by the Medicines for Malaria Venture in an effort to catalyze the discovery of drugs for the disease. The announcement comes amidst rapid shifts in the research around potential COVID-19 treatments. Just […] Continue reading ->
The combined impact of Covid-19 and malaria in regions where malaria is widespread “could be catastrophic,” warned David Reddy, CEO of Medicines for Malaria Venture (MMV), the Geneva-based product development partnership, just ahead of World Malaria Day, which is celebrated on Saturday, 25 April. His commment to Health Policy Watch,  came in the wake of […] Continue reading ->